Minetta C. Liu

18.2k total citations · 1 hit paper
204 papers, 6.0k citations indexed

About

Minetta C. Liu is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Minetta C. Liu has authored 204 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Cancer Research, 115 papers in Oncology and 77 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Minetta C. Liu's work include Cancer Genomics and Diagnostics (117 papers), Genetic factors in colorectal cancer (32 papers) and Breast Cancer Treatment Studies (32 papers). Minetta C. Liu is often cited by papers focused on Cancer Genomics and Diagnostics (117 papers), Genetic factors in colorectal cancer (32 papers) and Breast Cancer Treatment Studies (32 papers). Minetta C. Liu collaborates with scholars based in United States, United Kingdom and Japan. Minetta C. Liu's co-authors include Robert Clarke, Catherine Van Poznak, Robert C. Bast, Robert Mennel, Daniel F. Hayes, Fabrice André, Deborah Collyar, Nicole M. Kuderer, Nofisat Ismaila and Yue Wang and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Minetta C. Liu

188 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

2016 576 citations Minetta C. Liu, Catherine Van Poznak et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minetta C. Liu United States	36	3.4k	2.9k	1.9k	1.6k	736	204	6.0k
Rinat Yerushalmi Israel	27	4.4k 1.3×	2.3k 0.8×	2.2k 1.2×	1.8k 1.1×	1.2k 1.6×	119	6.7k
Lisa Rydén Sweden	44	2.7k 0.8×	2.8k 1.0×	2.1k 1.1×	1.1k 0.6×	772 1.0×	187	5.7k
Pär‐Ola Bendahl Sweden	44	3.3k 1.0×	3.0k 1.0×	2.7k 1.4×	1.4k 0.8×	928 1.3×	181	6.7k
Hervé Bonnefoi France	31	2.8k 0.8×	2.5k 0.9×	1.6k 0.8×	994 0.6×	588 0.8×	135	5.0k
Sherri R. Davies United States	19	3.3k 1.0×	4.0k 1.4×	3.0k 1.6×	1.0k 0.6×	891 1.2×	36	6.9k
Daniele Generali Italy	42	3.1k 0.9×	2.1k 0.7×	2.5k 1.3×	1.7k 1.0×	396 0.5×	232	6.2k
Otto Metzger United States	30	3.2k 0.9×	1.7k 0.6×	1.4k 0.7×	1.4k 0.8×	384 0.5×	117	4.8k
Grazia Arpino Italy	37	4.2k 1.2×	2.8k 1.0×	1.7k 0.9×	1.6k 1.0×	1.6k 2.2×	157	6.7k
Bjørn Naume Norway	45	3.4k 1.0×	3.1k 1.1×	2.5k 1.3×	1.1k 0.6×	615 0.8×	134	6.7k
Joaquı́n Mateo United Kingdom	34	3.3k 1.0×	1.8k 0.6×	2.1k 1.1×	3.2k 1.9×	606 0.8×	148	6.1k

Countries citing papers authored by Minetta C. Liu

Since Specialization

Citations

This map shows the geographic impact of Minetta C. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minetta C. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minetta C. Liu more than expected).

Fields of papers citing papers by Minetta C. Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minetta C. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minetta C. Liu. The network helps show where Minetta C. Liu may publish in the future.

Co-authorship network of co-authors of Minetta C. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Minetta C. Liu. A scholar is included among the top collaborators of Minetta C. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minetta C. Liu. Minetta C. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zariffa, Névine, Katherine K. Nishimura, Yu Deng, et al.. (2025). Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy. Journal for ImmunoTherapy of Cancer. 13(9). e012454–e012454.

Foldi, Julia, Steffi Oesterreich, Antony Tin, et al.. (2025). Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast. JCO Precision Oncology. 9(9). e2400577–e2400577.

Lee, Sarah S., Jingwen Zhang, Sara L. Bristow, et al.. (2024). A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.. Journal of Clinical Oncology. 42(16_suppl). 10596–10596. 1 indexed citations

Didelot, Audrey, Chloé Broudin, George Laliotis, et al.. (2024). Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): The PLAGAST prospective biomarker study.. Journal of Clinical Oncology. 42(16_suppl). 4028–4028. 2 indexed citations

Sfakianos, John P., George Laliotis, Clint Cary, et al.. (2024). Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer.. Journal of Clinical Oncology. 42(16_suppl). 5034–5034. 1 indexed citations

Souter, Vivienne, et al.. (2024). Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing. SHILAP Revista de lepidopterología. 4(1). 185–185.

Lee, Jeeyeon, et al.. (2024). Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments. Thoracic Cancer. 15(13). 1095–1102. 8 indexed citations

Basu, Arnab, Meenakshi Malhotra, Adam C. ElNaggar, et al.. (2024). Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. 8(8). e2400667–e2400667. 4 indexed citations

Pellini, Bruna, Russell W. Madison, Ole Gjoerup, et al.. (2023). Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(22). 4596–4605. 25 indexed citations

10.

Liu, Minetta C., Matthew MacKay, Christine Lo, et al.. (2022). Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. JCO Precision Oncology. 6(6). e2100321–e2100321. 16 indexed citations

11.

Thompson, Kevin J., Roberto A. Leon‐Ferre, Jason P. Sinnwell, et al.. (2022). Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 4(2). zcac018–zcac018. 26 indexed citations

12.

Viker, Kimberly, Ianko Iankov, Arun Ammayappan, et al.. (2022). Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene. Molecular Therapy — Methods & Clinical Development. 26. 532–546. 13 indexed citations

13.

Koh, Siang‐Boon, Kenneth N. Ross, Steven J. Isakoff, et al.. (2021). RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research. 27(17). 4883–4897. 16 indexed citations

14.

Chen, Xiaoji, Dong Zhao, Earl Hubbell, et al.. (2021). Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clinical Cancer Research. 27(15). 4221–4229. 79 indexed citations

15.

Carter, Jodi M., Mei‐Yin C. Polley, Roberto A. Leon‐Ferre, et al.. (2021). Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer. Clinical Cancer Research. 27(20). 5628–5637. 35 indexed citations

16.

Paoletti, Costanza, Meredith M. Regan, Samuel M. Niman, et al.. (2021). Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. npj Breast Cancer. 7(1). 77–77. 21 indexed citations

17.

Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations

18.

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations

19.

Paoletti, Costanza, Yufeng Li, Maria C. Muñiz, et al.. (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research. 21(12). 2771–2779. 75 indexed citations

20.

Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, et al.. (2014). Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research. 21(5). 1098–1105. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact